Shisi Pharmaceutical Group (02005) has obtained drug production registration approval from the State Drug Administration for ozagrelide sodium injection

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group has obtained approval from the China National Drug Administration for the production of ozagrelli sodium injections (5ml: 40mg and 2.5ml: 20mg), which is a Class 3 chemical drug and is deemed to have passed the consistency evaluation.

Ozagrel sodium injection is mainly used to treat acute thrombotic cerebral infarctions and movement disorders associated with cerebral infarctions. The Group has approved the launch of two major infusion specifications of Ozagrelli Sodium Chloride Injection (250ml: 80mg and 100ml: 80mg). This approval has achieved full dosage coverage of Ozagrel Sodium “Small Volume Injection+ Large Sodium Chloride Infusion”, which helps the Group further develop the neurology market.